Loading...
XWAR
SVE
Market cap72mUSD
Dec 05, Last price  
3.75PLN
1D
1.35%
1Q
-19.01%
Jan 2017
228.95%
IPO
-45.65%
Name

Biomed Lublin Wytwornia Surowic i Szczepionek SA

Chart & Performance

D1W1MN
XWAR:SVE chart
P/E
34.97
P/S
3.68
EPS
0.11
Div Yield, %
Shrs. gr., 5y
2.52%
Rev. gr., 5y
12.91%
Revenues
72m
+22.44%
30,931,45239,142,85424,642,25232,976,98933,575,56642,587,72336,339,00031,404,00032,293,00039,107,00040,159,00041,154,00050,383,00058,607,00071,756,000
Net income
8m
+58.68%
2,540,613524,59202,336,567163,2130-23,476,000588,000-32,412,0002,483,0004,439,0004,249,0006,081,0004,758,0007,550,000
CFO
14m
P
00000015,770,0004,356,000-620,0008,160,000343,000-3,281,0002,948,000-5,345,00013,726,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.
IPO date
Jul 29, 2011
Employees
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT